Dysregulation of immunity in COVID-19 and SLE.
Seyyed Sina HejazianSeyyedeh Mina HejazianFarahnoosh FarnoodSima Abedi AzarPublished in: Inflammopharmacology (2022)
The immune response plays a crucial role in preventing diseases, such as infections. There are two types of immune responses, specific and innate immunity, each of which consists of two components: cellular immunity and humoral immunity. Dysfunction in any immune system component increases the risk of developing certain diseases. Systemic lupus erythematosus (SLE), an autoimmune disease in the human body, develops an immune response against its own components. In these patients, due to underlying immune system disorders and receipt of immunosuppressive drugs, the susceptibility to infections is higher than in the general population and is the single largest cause of mortality in this group. COVID-19 infection, which first appeared in late 2019, has caused several concerns in patients with SLE. However, there is no strong proof of additional risk of developing COVID-19 in patients with SLE, and in some cases, studies have shown less severity of the disease in these individuals. This review paper discusses the immune disorders in SLE and COVID-19.
Keyphrases
- systemic lupus erythematosus
- immune response
- coronavirus disease
- disease activity
- sars cov
- end stage renal disease
- dendritic cells
- toll like receptor
- ejection fraction
- chronic kidney disease
- endothelial cells
- newly diagnosed
- multiple sclerosis
- respiratory syndrome coronavirus
- rheumatoid arthritis
- oxidative stress
- prognostic factors
- cardiovascular events
- drug induced
- pluripotent stem cells
- case control
- patient reported